Skip to content
International ABRAX Study with David Cibula episode artwork

Mar 9, 2021 47 min

International ABRAX Study with David Cibula

from IJGC Podcast Hosted by BMJ Group

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. David Cibula to discuss the international ABRAX study. Dr. Cibula is the Chair of the Gynecologic Oncology Center at the General Faculty Hospital in Prague, Chair of the Central and Eastern European Gynaecologic Oncology Group (CEEGOG), as well as a Former ESGO president. Highlights: * ABRAX trial was designed to evaluate if the completion of radical hysterectomy is associated with a survival benefit in patients with early-stage cervical cancer and positive pelvic lymph node found intraoperatively. * This trial represents the largest cohort of patients managed by upfront surgery with negative lymph nodes on preoperative staging but positive lymph node involvement diagnosed during surgery. * We did not find any improvement in PFS, OS, or pelvic disease-free survival associated with radical hysterectomy, either in the whole group or in any subgroups, including patients with larger tumor size or adenocarcinomas. * The outcome of the ABRAX trial is in agreement with current international guidelines (NCCN, ESGO-ESTRO-ESP) which recommend the abandonment of further radical surgery in patients with intraoperative N1 detection.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

International ABRAX Study with David Cibula

0:00 47:22

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of IJGC Podcast?

This episode is 47 minutes long.

When was this IJGC Podcast episode published?

This episode was published on March 9, 2021.

Can I download this IJGC Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.